| Spanish Wilson Disease Registry (NCT06466291) | Asociación Española para el Estudio del Hígado | 2021-12-02 |
| Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease (NCT05047523) | Alexion Pharmaceuticals, Inc. | 2021-09-13 |
| Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease (NCT04909346) | Ultragenyx Pharmaceutical Inc | 2021-06-23 |
| Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease (NCT04531189) | Ultragenyx Pharmaceutical Inc | 2020-12-11 |
| Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (NCT04422431) | Alexion Pharmaceuticals, Inc. | 2020-12-02 |
| Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (NCT04526210) | Alexion Pharmaceuticals, Inc. | 2020-10-21 |
| Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 (NCT04573309) | Alexion Pharmaceuticals, Inc. | 2020-09-07 |
| Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (NCT04526197) | Alexion Pharmaceuticals, Inc. | 2020-07-07 |
| Study of Retinal Vascular Parameters in Patients With Wilson's Disease (NCT04408300) | Fondation Ophtalmologique Adolphe de Rothschild | 2020-06-04 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease (NCT03539952) | Orphalan | 2018-09-03 |
| A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease (NCT03659331) | Prof. Elon Pras | 2018-09-01 |
| Establishment of Human Cellular Disease Models for Wilson Disease (NCT03867526) | CENTOGENE GmbH Rostock | 2018-06-19 |
| Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure (NCT03589820) | Third Affiliated Hospital, Sun Yat-Sen University | 2018-06-01 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (NCT03403205) | Alexion Pharmaceuticals, Inc. | 2018-02-22 |
| Natural History of Wilson Disease (NCT03334292) | Yale University | 2017-12-18 |
| The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment (NCT02763215) | Alexion Pharmaceuticals, Inc. | 2016-05-19 |
| Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine (NCT02426905) | Univar BV | 2016-01-01 |
| Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients (NCT02273596) | Alexion Pharmaceuticals, Inc. | 2014-11-24 |
| Inhibitory rTMS in Dystonic Wilson Patients (NCT01980433) | Assistance Publique - Hôpitaux de Paris | 2014-01-01 |
| Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients (NCT04965571) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2010-09-01 |
| Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease (NCT01472874) | Yale University | 2010-01-01 |
| French Wilson Disease Registry (NCT05231876) | Fondation Ophtalmologique Adolphe de Rothschild | 2005-01-01 |
| Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease (NCT04965545) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2004-01-01 |
| Study of Tetrathiomolybdate in Patients With Wilson Disease (NCT00004339) | National Center for Research Resources (NCRR) | 1994-01-01 |
| Study of Zinc for Wilson Disease (NCT00004338) | National Center for Research Resources (NCRR) | 1993-10-01 |
| Early Access Program for ALXN1840 in Patients With Wilson Disease (NCT05686564) | Alexion Pharmaceuticals, Inc. | |